---
title: MannLabs @2025
description: The Year 2025 in Review
toc: true
---

## Overview

{{< centered-table >}}
| Metric | Count |
| ------------------------------------- | --- |
| Last/Senior Author Papers (Published) | 18+ |
| Preprints (bioRxiv/medRxiv) | 9+ |
| Nature family papers | 7 |
| Major Collaborations | 6+ |
{{< /centered-table >}}

## Technology Advances

### Proteomics Methods

- **SPEC (Solid-Phase Extraction Capture)** Heymann T, Oliinyk D, Henneberg L, et al. _bioRxiv 2025.05.31.657165_<br>Nanoliter-volume workflow for fast, robust and ultrasensitive proteomics enabling unprecedented sensitivity from minimal sample input.

- **PCA-N Workflow for Plasma Proteomics** Albrecht V, Müller-Reif JB, Brennsteiner V, Mann M _Mol Cell Proteomics. 2025 Nov;24(11):101071_<br>Simplified perchloric acid workflow enabling deep plasma proteomics at population scale with \>10,000 samples per day throughput.

- **nanoPhos -- Spatial Phosphoproteomics** Oliinyk D, Heymann T, Henneberg L, et al. _bioRxiv 2025.05.29.656770_<br>Ultra-sensitive cell-type resolved spatial phosphoproteomics enabling signaling analysis at single-cell resolution in tissues.

- **PASEF Workflow Protocol** Skowronek P, Wallmann G, Wahle M, Willems S, Mann M _Nat Protoc. 2025 Jun;20(6):1700-1729_<br>Accessible step-by-step protocol for high-sensitivity proteomics using parallel accumulation-serial fragmentation.

- **Stellar MS for Biomarker Translation** Wahle M, Remes PM, Albrecht V, et al., Mann M _Mol Cell Proteomics. 2025 Sep;24(9):101050_<br>Novel hybrid high-speed mass spectrometer enables rapid translation from biomarker candidates to targeted clinical tests using 15N-labeled proteins.

- **Pre-Analytical Drivers of Bias in Plasma Proteomics** Korff K, Müller-Reif JB, et al., Mann M, Geyer PE _EMBO Mol Med. 2025 Nov;17(11):3174-3196_<br>Systematic evaluation of plasma proteomics workflows reveals susceptibility to cellular contamination and provides framework for quality control.

## Bioinformatics & Software

- **AlphaDIA -- Transfer Learning for DIA** Wallmann G, Skowronek P, Brennsteiner V, et al., Mann M _Nat Biotechnol. 2025 Oct 21_<br>End-to-end transfer learning enabling feature-free proteomics with dramatically improved identification rates.

- **scPortrait -- Single-Cell Image Integration** Mädler SC, Schmacke NA, Palma A, et al., Theis FJ, Mann M _bioRxiv 2025.09.22.677590_<br>Software package for generation, storage and application of single-cell image datasets enabling multimodal analysis.

- **Tree-based Proteoform Quantification** Ammar C, Thielert M, Weiss CAM, et al., Mann M _bioRxiv 2025.03.06.641844_<br>Novel computational approach to infer proteoform regulation from bottom-up proteomics data.

- **AI Laboratory Agents** Skowronek P, Nawalgaria A, Mann M _Mol Syst Biol. 2025 Dec_<br>Multimodal AI agents for capturing and sharing tacit laboratory practice through video, speech, and text analysis.

## High-Throughput Applications

### Clinical & Population Proteomics

- **ADAPT-MS Clinical Framework** Müller-Reif JB, Albrecht V, et al., Wewer Albrechtsen NJ, Mann M _In press at Nature Communications_<br>Adaptive diagnostic framework for clinical proteomics enabling personalized testing from plasma and CSF.

- **Plasma Proteome in Children and Adolescents** Niu L, Stinson SE, Holm LA, et al., Mann M _Nat Genet. 2025 Feb 19_<br>Comprehensive proteomic profiling of 2,147 children revealing associations with age, sex, puberty, BMI, and genetics.

- **Ontology-guided Clustering for Rare Pediatric Disorders** Itang ECM, Albrecht V, et al., Mann M, Pangratz-Fuehrer S, Mueller-Reif JB _EMBO Mol Med. 2025 Jul;17(7):1842-1867_<br>Framework integrating clinical ontologies with proteomics enables analysis of 394 rare pediatric conditions from 1,140 patients.

### Disease Biology & Spatial Proteomics

- **Alpha-1 Antitrypsin Deficiency -- Liver Disease** Rosenberger FA, Mädler SC, et al., Mann M _Nature. 2025 Apr 16_<br>Deep Visual Proteomics reveals why some patients with the hereditary liver disease remain healthy while others develop severe pathology.

- **Liver Zonation and Fibrosis** Weiss CAM, Brown LA, Miranda L, et al., Rosenberger FA, Mann M _bioRxiv 2025.04.13.648568_<br>Single cell spatial proteomics maps human hepatocyte zonation patterns and their vulnerability to fibrosis.

- **Colon Organoid Models** Post F, Hausmann A, et al., Mann M _Cell Syst. 2025 Sep 17;16(9):101396_<br>DVP reveals in vivo-like phenotype upon xenotransplantation of human colon organoids.

- **Pancreatic Islet Cell Diversity** Thielert M, Villalba A, et al., Mann M, Scharfmann R _Commun Biol. 2025 Oct 17;8(1):1483_<br>Cell type-resolved proteomics and phosphoproteomics decode adult murine pancreatic islet cell diversity.

- **Signet Ring Cell Carcinoma** Kabatnik S, Zheng X, et al., Mann M _NPJ Precis Oncol. 2025 Feb 5;9(1):37_<br>DNA replication stress identified as a hallmark of signet ring cell carcinoma through DVP.

- **Tumor-Immune Crosstalk** Zheng X, Mund A, Mann M _Mol Cell. 2025 Mar 6;85(5):1008-1023.e7_<br>Deciphering functional tumor-immune crosstalk through highly multiplexed imaging and deep visual proteomics.

## Major Collaborations

### Ovarian Cancer -- Ernst Lengyel (U. Chicago)

- **Borderline Ovarian Tumor Progression (LGSC)** Schweizer L, Kenny HA, et al., Mann M, Lengyel E _Cancer Cell. 2025 Jun 20_<br>Spatial proteo-transcriptomics reveals molecular landscape of borderline ovarian tumors. Identified 16 drug targets; combination therapy achieved significant tumor reduction.

- **Early Ovarian Cancer Mechanisms (HGSC)** Metousis A, Kenny HA, Shimizu A, et al., Mann M, Lengyel E _medRxiv 2025.08.25.25333715_<br>Integration of cell-type resolved spatial proteomics and transcriptomics reveals novel mechanisms including SUMOylation activation and ATR signaling.

- **NNMT Inhibition Restores Antitumor Immunity** Heide J, Bilecz AJ, et al., Mann M, \..., Lengyel E _Nature. 2025 Sep;645(8082):1051-1059_<br>NNMT inhibitor reduces tumor burden by reprogramming cancer-associated fibroblasts and restoring immune checkpoint blockade efficacy.

- **3D Multi-omic Mapping of Fallopian Tubes (STIC)** Metousis A, et al., Mann M, Lengyel E _bioRxiv 2025.09.21.677628_<br>Spatially resolved multi-omics framework identifies 99 STICs and precursors in cancer-free organ donors, revealing high incidence of ovarian cancer precursors.

### Clinical Proteomics -- Nicolai Wewer Albrechtsen (Copenhagen)

- **Diagnostic potential of proteomics in Lyme disease** Nielsen AB, Fjordside L, Drici L, et al. _Nat Commun 16, 9322 (2025)_<br>This report highlights the potential of proteomics to inform Machine Learning-assisted diagnostics. 

### Other Key Collaborations

- **GPX4 and Ferroptosis in Neurodegeneration** Lorenz SM, et al., Mann M, \..., Conrad M _Cell. 2025 Dec (with Marcus Conrad, Helmholtz Munich)_<br>A fin-loop-like structure in GPX4 underlies neuroprotection from ferroptosis. Proteomics revealed Alzheimer's-like signatures.

- **LRRK2 and Crohn's Disease/Colitis** Heaton GR, et al., Mann M, \..., Yue Z _J Clin Invest. 2025 Oct (with Zhenyu Yue, Mount Sinai)_<br>Targeting specific LRRK2 kinase substrates rescues colitis severity caused by Crohn's disease-linked variant.

- **GID E3 Ligase Complex** Schulman lab with Mann lab proteomics _Multiple papers ongoing_<br>Continued collaboration on ubiquitin signaling including LRRC58/CDO1 cysteine availability studies.

## Clinical Impact Highlight

**JAK Inhibitors for Toxic Epidermal Necrolysis**

[Our 2024 _Nature_ publication (Nordmann TM et al.)](https://doi.org/10.1038/s41586-024-08061-0) on spatial proteomics
identifying JAK inhibitors as treatment for toxic epidermal necrolysis
(TEN) -- a lethal skin disease -- has had immediate clinical impact in 2025. Off-label use of JAK inhibitors in the first patients worldwide
led to complete recovery.

_\"To our knowledge, this is the first time a spatial omics technology
has made an immediate and tangible impact in the clinic, by identifying
a treatment that has already changed people\'s lives for the good.\"_

--- Matthias Mann

## 2025 Preprints (bioRxiv/medRxiv)

- **SPEC workflow** Heymann et al. _bioRxiv May 2025_<br>Solid-Phase Extraction Capture for ultrasensitive proteomics

- **nanoPhos** Oliinyk et al. _bioRxiv May 2025_<br>Cell-type resolved spatial phosphoproteomics

- **Liver zonation** Weiss et al. _bioRxiv Apr 2025_<br>Single cell spatial proteomics of hepatocyte zonation

- **Tree-based proteoform quantification** Ammar et al. _bioRxiv Mar 2025_<br>Inferring proteoform regulation from bottom-up data

- **ADAPT-MS** Müller-Reif et al. _medRxiv May 2025 (in press Nat Commun)_<br>Adaptive clinical diagnostics framework

- **scPortrait** Mädler et al. _bioRxiv Sep 2025_<br>Single-cell image integration for multimodal modeling

- **Early ovarian cancer (HGSC)** Metousis et al. _medRxiv Aug 2025_<br>Spatial proteomics/transcriptomics integration

- **3D fallopian tube mapping (STIC)** Metousis et al. _bioRxiv Sep 2025_<br>Multi-omic mapping revealing ovarian cancer precursors

- **Pre-analytical bias** Korff et al. _bioRxiv May 2025 (now published EMBO Mol Med)_<br>Bias in bead-enriched plasma proteomics

## Publication Summary by Journal

{{< centered-table >}}
| Journal | Count | Topics |
| --- | --- | --- |
| _Nature_ | 3 | Liver disease (DVP), Review, NNMT/CAFs (w/ Lengyel) |
| _Nature Biotechnology_ | 1 | AlphaDIA transfer learning |
| _Nature Genetics_ | 1 | Pediatric plasma proteome |
| _Nature Protocols_ | 1 | PASEF workflow |
| _Nature Communications_ | 1 | ADAPT-MS (in press) |
| _Cancer Cell_ | 1 | Ovarian cancer progression (w/ Lengyel) |
| _Cell_ | 1 | GPX4 ferroptosis (w/ Conrad) |
| _Cell Systems_ | 1 | Colon organoid DVP |
| _EMBO Mol Med_ | 2 | Rare pediatric disorders, Pre-analytical bias |
| _Molecular Cell_ | 1 | Tumor-immune crosstalk |
| _Mol Cell Proteomics_ | 2 | PCA-N plasma, Stellar MS |
| _Commun Biol_ | 1 | Pancreatic islet cells |
| _NPJ Precision Oncol_ | 1 | Signet ring cell carcinoma |
| _Mol Syst Biol_ | 1 | AI laboratory agents |
| _J Clin Invest_ | 1 | LRRK2 colitis (w/ Yue) |
{{< /centered-table >}}